Top

Published in:

01-08-2021 | Systemic Therapy | Special Section: HCC treatment

Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention

Authors: Joseph H. Yacoub, David Mauro, Andrew Moon, Aiwu R. He, Mustafa R. Bashir, Christine C. Hsu, Thomas M. Fishbein, Lauren M. B. Burke

Published in: Abdominal Radiology | Issue 8/2021

Abstract

Locoregional therapies can be offered to hepatocellular carcinoma patients as a bridge to transplant, to downstage disease burden for transplant eligibility, or for disease control to prolong survival. Systemic therapies also play a large role in HCC treatment, occasionally in conjunction with other methods. This manuscript reviews the various treatment options for HCC with a historically noncurative intent.

Brown KT, Do RK, Gonen M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34(17):2046–2053. https://doi.org/10.1200/JCO.2015.64.0821.CrossRefPubMedPubMedCentral

Raoul J-L, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37(3):212–220. https://doi.org/10.1016/j.ctrv.2010.07.006.CrossRefPubMed

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429–442. https://doi.org/10.1053/jhep.2003.50047.CrossRefPubMed

Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;(3)https://doi.org/10.1002/14651858.cd004787.pub2.

Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47–54. https://doi.org/10.1148/radiol.2241011262.CrossRefPubMed

Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30(1):6–25. https://doi.org/10.1007/s00270-006-0062-3.CrossRefPubMed

Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. Hepatology; 2011. p. 1020–1022https://doi.org/10.1002/hep.24199.

Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. https://doi.org/10.1016/j.jhep.2011.12.001.CrossRef

Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33(3):541–551. https://doi.org/10.1007/s00270-009-9750-0.CrossRefPubMed

10.

Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION v study. Cardiovasc Intervent Radiol. 2010;33(1):41–52. https://doi.org/10.1007/s00270-009-9711-7.CrossRefPubMed

11.

Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–264. https://doi.org/10.1038/bjc.2014.199.CrossRefPubMedPubMedCentral

12.

Cheng AL, Amarapurkar D, Chao Y, et al. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int. 2014;34(2):174–183. https://doi.org/10.1111/liv.12314.CrossRefPubMed

13.

Mähringer-Kunz A, Kloeckner R, Pitton MB, et al. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2017;40(7):1017–1025. https://doi.org/10.1007/s00270-017-1606-4.CrossRefPubMed

14.

Yuan-Dong S, Hao Z, Hui-Rong X, et al. Combination therapy: Meta-analysis of the effects of TACE and cryoablation on hepatocellular carcinoma. Med (United States). 2019;98(49)https://doi.org/10.1097/MD.0000000000018030.

15.

Li L, Tian J, Liu P, Wang X, Zhu Z. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: A meta-analysis. Tumori. 2016;102(3):301–310. https://doi.org/10.5301/tj.5000491.CrossRef

16.

Chen QF, Jia ZY, Yang ZQ, Fan WL, Shi H Bin. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization–Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center. Cardiovasc Intervent Radiol. 2017;40(11):1748–1755. https://doi.org/10.1007/s00270-017-1736-8.

17.

Xu LF, Sun HL, Chen YT, et al. Large primary hepatocellular carcinoma: Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28(3):456–463. https://doi.org/10.1111/jgh.12088.CrossRefPubMed

18.

Sacco R, Conte C, Tumino E, et al. Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;Volume 3:25–29. https://doi.org/10.2147/jhc.s50359.CrossRefPubMedPubMedCentral

19.

Tong AKT, Kao YH, Too CW, Chin KFW, Ng DCE, Chow PKH. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016;89(1062):20150943. https://doi.org/10.1259/bjr.20150943.CrossRefPubMedPubMedCentral

20.

Kim H-C. Radioembolization for the treatment of hepatocellular carcinoma. Clin Mol Hepatol. 2017;23(2):109–114. https://doi.org/10.3350/cmh.2017.0004.CrossRefPubMedPubMedCentral

21.

Ward TJ, Tamrazi A, Lam MGEH, et al. Management of High Hepatopulmonary Shunting in Patients Undergoing Hepatic Radioembolization. J Vasc Interv Radiol. 2015;26(12):1751–1760. https://doi.org/10.1016/j.jvir.2015.08.027.CrossRefPubMed

22.

Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology. 2010;138(1):52–64. https://doi.org/10.1053/j.gastro.2009.09.006.CrossRefPubMed

23.

Hilgard P, Hamami M, Fouly A El, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741–1749. https://doi.org/10.1002/hep.23944.CrossRefPubMed

24.

Sangro B, Carpanese L, Cianni R, et al. Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011;54(3):868–878. https://doi.org/10.1002/hep.24451.CrossRefPubMed

25.

Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;151(6):1155-1163.e2. https://doi.org/10.1053/j.gastro.2016.08.029.CrossRefPubMed

26.

Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497-507.e2. https://doi.org/10.1053/j.gastro.2010.10.049.CrossRefPubMed

27.

Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology. 2018;287(3):1050–1058. https://doi.org/10.1148/radiol.2018171768.CrossRefPubMed

28.

Elsayed M, Ermentrout RM, Sethi I, et al. Incidence of Radioembolization-Induced Liver Disease and Liver Toxicity Following Repeat 90Y-Radioembolization: Outcomes at a Large Tertiary Care Center. Clin Nucl Med. 2020;45(2):100–104. https://doi.org/10.1097/RLU.0000000000002828.CrossRefPubMed

29.

Miften M, Vinogradskiy Y, Moiseenko V, et al. Radiation Dose-Volume Effects for Liver SBRT. Int J Radiat Oncol Biol Phys. 2018;https://doi.org/10.1016/j.ijrobp.2017.12.290.CrossRefPubMedPubMedCentral

30.

Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. https://doi.org/10.1002/hep.29913.CrossRefPubMed

31.

Benson AB, D’Angelica MI, Abbott DE, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. J Natl Compr Cancer Netw. 2019;17(4):302–310. https://doi.org/10.6004/jnccn.2019.0019.

32.

Wahl DR, Stenmark MH, Tao Y, et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol. 2016;34(5):452–459. https://doi.org/10.1200/JCO.2015.61.4925.CrossRefPubMed

33.

Kim N, Kim HJ, Won JY, et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019;131:81–87. https://doi.org/10.1016/j.radonc.2018.12.013.CrossRefPubMed

34.

Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-Associated Liver Injury. Int J Radiat Oncol Biol Phys. 2010;76(3 SUPPL.)https://doi.org/10.1016/j.ijrobp.2009.06.092.

35.

Schefter TE, Rusthoven KE, Kavanagh BD, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–1578. https://doi.org/10.1200/JCO.2008.19.6329.CrossRefPubMed

36.

Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78(2):486–493. https://doi.org/10.1016/j.ijrobp.2009.08.020.CrossRefPubMed

37.

Lee MT, Kim JJ, Dinniwell R, et al. Phase i study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–1591. https://doi.org/10.1200/JCO.2008.20.0600.CrossRefPubMed

38.

Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631–1639. https://doi.org/10.1200/JCO.2012.44.1659.CrossRefPubMed

39.

Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4)https://doi.org/10.1016/j.ijrobp.2011.04.011.

40.

Kang J-K, Kim M-S, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012;118(21):5424–5431. https://doi.org/10.1002/cncr.27533.CrossRefPubMed

41.

Bae SH, Kim MS, Cho CK, Kim KB, Han CJ, Kim YH. Feasibility and efficacy of stereotactic ablative radiotherapy for: Barcelona clinic liver cancer-C stage hepatocellular carcinoma. J Korean Med Sci. 2013;28(2):213–219. https://doi.org/10.3346/jkms.2013.28.2.213.CrossRefPubMedPubMedCentral

42.

Barney BM, Olivier KR, Miller RC, Haddock MG. Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol. 2012;7(1)https://doi.org/10.1186/1748-717X-7-67.

43.

Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;84(2):355–361. https://doi.org/10.1016/j.ijrobp.2011.11.058.CrossRefPubMed

44.

Cárdenes HR, Price TR, Perkins SM, et al. Phase i feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12(3):218–225. https://doi.org/10.1007/s12094-010-0492-x.CrossRefPubMed

45.

Kim JW, Seong J, Lee IJ, Woo JY, Han KH. Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. Oncotarget. 2016;7(26):40756–40766. https://doi.org/10.18632/oncotarget.9450.CrossRefPubMedPubMedCentral

46.

Moon DH, Wang AZ, Tepper JE. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol. 2018;126(3):527–533. https://doi.org/10.1016/j.radonc.2018.01.004.CrossRefPubMed

47.

Feng M, Suresh K, Schipper MJ, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage a phase 2 clinical trial. JAMA Oncol. 2018;4(1):40–47. https://doi.org/10.1001/jamaoncol.2017.2303.CrossRefPubMed

48.

Hara K, Takeda A, Tsurugai Y, et al. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. Hepatology. 2019;69(6):2533–2545. https://doi.org/10.1002/hep.30591.CrossRefPubMed

49.

Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92–99. https://doi.org/10.1016/j.jhep.2017.02.022.

50.

Bush DA, Smith JC, Slater JD, et al. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. Int J Radiat Oncol Biol Phys. 2016;95(1):477–482. https://doi.org/10.1016/j.ijrobp.2016.02.027.CrossRefPubMed

51.

Huang Y, Chen SW, Fan CC, Ting LL, Kuo CC, Chiou JF. Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma. Radiat Oncol. 2016;11(1)https://doi.org/10.1186/s13014-016-0663-1.

52.

Seol SW, Yu J Il, Park HC, et al. Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. Radiat Oncol J. 2015;33(4):276–283. https://doi.org/10.3857/roj.2015.33.4.276.

53.

McDuff SGR, Remillard KA, Zheng H, et al. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018;8(6):414–421. https://doi.org/10.1016/j.prro.2018.04.012.CrossRefPubMed

54.

Gkika E, Strouthos I, Kirste S, et al. Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlentherapie und Onkol. 2019;195(3):246–253. https://doi.org/10.1007/s00066-018-1385-0.CrossRef

55.

Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48(6):598–609. https://doi.org/10.1111/apt.14913.CrossRefPubMedPubMedCentral

56.

Mody K, Abou-Alfa GK. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. Curr Treat Options Oncol. 2019;20(1):3. https://doi.org/10.1007/s11864-019-0601-1.CrossRefPubMed

57.

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med. 2008;359(4):378–390. https://doi.org/10.1056/NEJMoa0708857.CrossRefPubMed

58.

Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.CrossRefPubMed

59.

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1.CrossRefPubMed

60.

Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.CrossRefPubMed

61.

Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54–63. https://doi.org/10.1056/NEJMoa1717002.CrossRefPubMedPubMedCentral

62.

El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2.CrossRefPubMedPubMedCentral

63.

Yau T, Park JW, Finn RS, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v874–v875. https://doi.org/10.1093/annonc/mdz394.029.CrossRef

64.

Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38(3):193–202. https://doi.org/10.1200/JCO.19.01307.CrossRefPubMed

65.

Yau T, Kang Y-K, Kim T-Y, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. J Clin Oncol. 2019;37(15_suppl):4012–4012. https://doi.org/10.1200/jco.2019.37.15_suppl.4012.

66.

FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma | FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma. Accessed August 15, 2020.

67.

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. https://doi.org/10.1056/NEJMoa1915745.CrossRefPubMed

68.

Zhu AX, Kang Y-K, Yen C-J, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. https://doi.org/10.1016/S1470-2045(18)30937-9.CrossRefPubMed

69.

FDA approves ramucirumab for hepatocellular carcinoma | FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma. Accessed August 15, 2020.

70.

FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma | FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma. Accessed August 15, 2020.

71.

Kelley RK. Atezolizumab plus Bevacizumab — A Landmark in Liver Cancer. N Engl J Med. 2020;382(20):1953–1955. https://doi.org/10.1056/NEJMe2004851.CrossRefPubMed

72.

Kudo M. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers (Basel). 2018;10(11):412. https://doi.org/10.3390/cancers10110412.CrossRefPubMedCentral

73.

Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. https://doi.org/10.1002/hep.29086.CrossRefPubMed

74.

Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019;Online ahehttps://doi.org/10.1136/gutjnl-2019-318934.

75.

Chow PKH, Gandhi M, Tan S-B, et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018;36(19):1913–1921. https://doi.org/10.1200/JCO.2017.76.0892.CrossRefPubMed

76.

Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636. https://doi.org/10.1016/S1470-2045(17)30683-6.CrossRefPubMed

77.

Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr. 2018;7(6):487–489. https://doi.org/10.21037/hbsn.2018.10.06.

Title: Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention
Authors: Joseph H. Yacoub
David Mauro
Andrew Moon
Aiwu R. He
Mustafa R. Bashir
Christine C. Hsu
Thomas M. Fishbein
Lauren M. B. Burke
Publication date: 01-08-2021
Publisher: Springer US
Keywords: Systemic Therapy
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Sorafenib
Published in: Abdominal Radiology / Issue 8/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-021-03074-z

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2021

Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE): a 20-year single-center clinical and radiologic experience

Percutaneous ablation versus surgical ablation and resection of liver tumors: medicare volume and physician reimbursement trends from 2010 to 2018

Radiofrequency versus microwave ablation for hepatocellular carcinoma within the Milan criteria in challenging locations: a retrospective controlled study

Introduction to the special section on hepatocellular carcinoma treatment response

The absolute tumor-capsule contact length in the diagnosis of extraprostatic extension of prostate cancer

Preoperative evaluation of extramural venous invasion in rectal cancer using radiomics analysis of relaxation maps from synthetic MRI

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page